Silica from sepiolite: Preparation, textural properties, and use as support to catalysts

Microwave assisted acid treatment of sepiolite: The role of composition and “crystallinity”

“…However, the crystal lattice of sepiolite is not entirely disrupted despite the acid treatment. The correlation between the quantity of Mg 2+ ions released from sepiolite and its properties, mainly an increase of the surface area (Aznar et al, 1996;Inukai et al, 1994) and the ability for adsorption on acid-activated sepiolite, have been reported in several studies (Kara et al, 2003;Sabah et al, 2002;Vico, 2003).…”

The Effect of Surface Modification of Silica Microfillers in an Epoxy Matrix on the Thermo-mechanical Properties

“…(Madrid, Spain) and used as reinforcement in an epoxy matrix. The SiO 2 content was around 90% (w/w), the specific surface area was 500 m 2 /g and the maximum water content was 1.5% (w/w) [20] as checked by thermogravimetry. The silica particles were fibers with a length of 0.2-1.0 µm arranged in bundles of about 50 nm.…”

“…Silica particles SMF2, prepared according to the methods described in [19,20], were supplied by Tolsa S. A. (Madrid, Spain) and used as reinforcement in an epoxy matrix.…”

Controlled Release of Acyclovir Through Bioengineered Corneal Implants with Silica Nanoparticle Carriers~!2009-08-29~!2010-01-05~!2010-03-18~!

“…However, in vivo applications are still proble-matic as both drugs and their carriers are rapidly cleared from the ocular surface by tearing and blinking. Hence, incorporation of carriers into a retentive ophthalmic ointment [19] or into contact lenses [22] have been proposed as means of extending drug availability to the ocular surface. However, to remedy HSV-induced vision loss, instead of treating the cornea with drugs and performing allograft surgery as two separate modalities, both with limited success rates, our results indicate that it would be possible to incorporate the drug/carrier directly into biosynthetic substitutes of human donor corneas [11,12], to allow for the drug to be released after implantation to prevent viral re-activation and re-infection.…”

“…Such ACV containing corneal substitutes will be suitable for high risk transplant patients with latent HSV, aiding in the prevention of HSVreactivation triggered by the surgery. Silica (SiO 2 ) nanoparticles (NP) (diameter < 100 nm) were selected as a prototype delivery vehicle, as they are simple to prepare and a range of methods for preparing porous SiO 2 NP are available [14,[22][23][24][25][26][27][28]. The microemulsion and reversed micelle (with HCl) method [29][30][31] was selected, as the water-oil microemulsion effectively encapsulates hydrophobic drugs (such as ACV), by dissolving the drug in the oil phase [17].…”